Determination of peripheral immune cell activity during treatment with either surgery or radiotherapy in patients with early stage non-small cell lung cancer.

Determination of peripheral immune cell activity during treatment with either surgery or radiotherapy in patients with early stage non-small cell lung cancer. - HAMLET study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39912

Enrollment

Registered

2013-05-07

Start date

2013-09-24

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer lung carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Cytologically or histologically proven cT1-2aN0M0 NSCLC - Patients >= 18 years old - Patients should be fit to undergo both treatments in accordance with institutional protocols

Exclusion criteria

Exclusion criteria: - Patients with any sign of any co-existing infectious disease or immunosuppressive treatment (inhalation steroids are permitted) - Mentally incapacitated subjects

Design outcomes

Primary

Measure	Time frame
To determine whether an increase in CD8 activity can be observed in patients with early stage lung cancer who undergo surgical intervention or SABR.	—

Secondary

Measure	Time frame
The number and activation status of CD4 positive cells, monocytes, Tregs and MDSC in patients with early stage lung cancer undergoing curative intervention (surgery or SABR).	—

Countries

Netherlands

Outcome results